Chemical degradation kinetics of recombinant hirudin (HV1) in aqueous solution: Effect of pH

Pharmaceutical Research

Volumn 15, Issue 9, 1998, Pages 1456-1462

  Gietz, Ursula ^a   Alder, Ruth ^a   Langguth, Peter ^a   Arvinte, Tudor ^b   Merkle, Hans P ^a  

^a ETH ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Capillary electrophoresis; Chemical stability; Circular dichroism; Cyclic imide formation; Isomerization; Protein stability; Recombinant hirudin; Succinimide formation

Indexed keywords

LEPIRUDIN;

AQUEOUS SOLUTION; ARTICLE; CAPILLARY ELECTROPHORESIS; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DENATURATION; DRUG DEGRADATION; DRUG STABILITY; KINETICS; PH; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BUFFERS; CIRCULAR DICHROISM; ELECTROPHORESIS, CAPILLARY; HIRUDINS; HYDROGEN-ION CONCENTRATION; KINETICS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN DENATURATION; RECOMBINANT PROTEINS; SOLUTIONS; TEMPERATURE; THROMBIN; WATER;

EID: 0031722913     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011918108849     Document Type: Article

References (26)

1. F. Markwardt. Untersuchungen über Hirudin. Naturwissenschaften 42:537-538 (1955).
2. W. E. Märki, H. Grossenbacher, M. G. Grütter, M. H. Liersch, B. Meyhack, and J. Heim. Recombinant hirudin: genetic engineering and structure analysis. Semin. Thromb. Hemostasis 17:88-93 (1991).
3. J.-Y. Chang. Stability of hirudin, a thrombin-specific inhibitor. J. Biol. Chem. 266(17):10839-43 (1991).
4. H. Grossenbacher, W. Märki, M. Coulot, D. Müller, and W. J. Richter. Characterization of succinimide-type dehydration products of recombinant hirudin variant 1 by electrospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry 7:1082-1085 (1993).
5. S. Capasso, L. Mazzarella, F. Sica, A. Zagari, and S. Salvadori. Spontaneous cyclization of the aspartic acid side chain to the succinimide derivative. J. Chem. Soc. Chem. Commun. 919-921 (1992).
6. T. Geiger and St. Clarke. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. J. Biol. Chem. 262(2):785-794 (1987).
7. St. J. Wearne and T. E. Creighton. Effect of protein conformation on rate of deamidation: Ribonuclease A. Proteins 5:8-12 (1989).
8. M. Xie, D. V. Velde, M. Morton, R. T. Borchardt, and R. L. Schowen. pH-induced change in the rate-determining step for the hydrolysis of the Asp/Asn- derived cyclic-imide intermediate in protein degradation. J. Am. Chem. Soc. 118:8955-8956 (1996).
9. P. Schindler, D. Müller, W. Märki, H. Grossenbacher, and W. J. Richter. Characterization of a β-Asp33 isoform of recombinant hirudin sequence Variant 1 by low-energy collision-induced dissociation. J. Mass Spectrom. 24:967-974 (1996).
10. A. Tuong, M. Maftouh, C. Ponthus, O. Whitechurch, C. Roitsch, and C. Picard. Characterization of the deamidated forms of recombinant hirudin. Biochemistry 31:8291-8299 (1992).
11. A. P. Nordmann. Spectroscopic and related studies of recombinant hirudin, human neuropeptide Y and analogues. Ph.D. Thesis, Birkheck College, London, 1996, p. 41.
12. S. J. Advant. The effect of solution environment on the stability and aggregation of recombinant human interleukin-2. Ph.D. Thesis, University of Connecticut, U.M.I. Publ., Ann Arbor (MI), USA, 1994, pp. 31-34.
13. F. Markwardt. The development of hirudin as an antithrombotic drug. Thromb. Res. 74(1):1-23 (1994).
14. H. Haruyama and K. Wüthrich. Conformation of recombinant desulfatohirudin in aqueous solution determined by nuclear magnetic resonance. Biochemistry 28:4301-4312 (1989).
15. K. Forrer, P. Girardot, M. Dettwiler, W. Märki, H. Grossenbacher, and E. Gassmann. Different modes of capillary electrophoresis for the analysis of recombinant hirudin. 9th International Symposium on Capillary Electrophoresis, Budapest, Hungary, 1994.
16. C. Dette and H. Wätzig. Separation of r-hirudin from similar substances by capillary electrophoresis. J. Chromatogr. A 700: 89-94 (1995).
17. U. Gietz. Therapeutic protein formulation for sustained delivery: Formulation aspects and stability. Ph.D. Thesis, Department of Pharmacy ETH. Zurich, 1997.
18. S. Clarke. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int. J. Peptide Protein Res. 30:808-821 (1987).
19. A. A. Kossiakoff. Tertiary structure is a principal determinant to protein deamidation. Science 240:191-194 (1988).
20. C. Oliyai and R. T. Borchardt. Chemical pathways of peptide degradation. IV. Pathways, kinetics and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm. Res. 10:95-102 (1993).
21. T. V. Brennan and St. Clarke. Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: Effect of the solvent dielectric. Protein Sci. 2:331-338 (1993).
22. T. J. Ahern and A. M. Klibanov. The mechanism of irreversible enzyme inactivation at 100°C. Science 228:1280-1284 (1985).
23. R. Pearlman and T. A. Bewley. Stability and characterization of human growth hormone. In: Y. J. Wang and R. Pearlman (eds.). Stability and characterization of protein and peptide drugs. Plenum Press. New York, 1993, pp 1.
24. R. I. Senderoff, S. C. Wootton, A. M. Boctor, T. M. Chen, A. B. Giordani, T. N. Julian, and G. W. Radebaugh. Aqueous stability of human epidermal growth factor 1-48. Pharm. Res. 11(12):1712-1720 (1994).
25. A. Otto and R. Seckler. Characterization, stability and refolding of recomhinant hirudin. Eur. J. Biochem. 202:67-73 (1991).
26. R. Khurana, A. T. Hate, U. Nath, and J. B. Udgaonkar. pH dependence of the stability of barstar to chemical and thermal denaturation. Protein Science 4:1133-1144 (1995).